The 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025), was held from June 15–19, 2025, in Bruges, Belgium. This “Column Watch” installment ...

The government has announced plans to set up the National Centre for Advanced Materials (NCAM) at Quaid-i-Azam University, ...

Language connects people. For entrepreneurs, being fluent in more than one language is more than a practical skill—it builds the confidence to communicate, lead, and grow in international markets.

Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with ...

About PBGENE-HBV (Viral Elimination Program): PBGENE-HBV is Precision’s wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to ...

Late-breaking oral presentation of interim safety and efficacy data from the phase 1 study of SBT-77-7101, including a favorable early safety profile, with preliminary clinical and mechanistic ...

Leuven, Belgium. October 6, 2025. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced ...

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, ...

Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings On track for full data read out in the first half of 2026 Discovery and preclinical data on O3R-5671 selected for ...

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...